Quick Answer
Vivos Therapeutics, Inc. reported Cash and Equivalents of $6.26 million for fiscal year 2024.
Vivos Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $6.26M | +281.0% |
| 2023 | $1.64M | -53.3% |
| 2022 | $3.52M | -85.4% |
| 2021 | $24.03M | +32.0% |
| 2020 | $18.21M | +3779.0% |
| 2019 | $469.4K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.09M | -51.1% | -29.9% |
| June 30, 2025 | $4.40M | -36.2% | +88.0% |
| March 31, 2025 | $2.34M | -10.3% | -62.6% |
| December 31, 2024 | $6.26M | +281.0% | -0.8% |
| September 30, 2024 | $6.31M | +538.8% | -8.6% |
| June 30, 2024 | $6.90M | +75.1% | +164.4% |
| March 31, 2024 | $2.61M | -62.9% | +58.9% |
| December 31, 2023 | $1.64M | -53.3% | +66.3% |
- Vivos Therapeutics, Inc. showed an increase of +281.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2024 period, Vivos Therapeutics, Inc.’s cash and equivalents has grown by 1233.8% (from $469.4 thousand to $6.26 million).
- The most recent figure is from Vivos Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: